EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biomarker Validation in NPC1 : Foundations for Clinical Trials and Regulatory Alignment

Krista Casazza iD, Stephanie M Cologna, Elizabeth Berry-Kravis, Jeanine Jarnes, Forbes D Porter

Journal of Inherited Metabolic Disease · 2025-09 · 48 (5)

DOI: 10.1002/jimd.70075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 15.08.2025. Verfasst von Krista Casazza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Purity Health, Columbia, Tennessee, USA. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Intramural NIH HHS, US FDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Niemann–Pick Type C1 (NPC1) disease is a rare, autosomal recessive, neurovisceral lysosomal storage disorder caused by mutations in the NPC1 . This condition leads to defective intracellular cholesterol and lipid trafficking, resulting in the accumulation of unesterified cholesterol and glycosphingolipids in late endosomes and lysosomes. Clinically, NPC1 manifests with a heterogeneous spectrum of progressive neurological symptoms, including ataxia, vertical supranuclear gaze palsy, dysarthria, cognitive decline, and dystonia, often accompanied by systemic signs such as hepatosplenomegaly and neonatal cholestasis. The age of neurological symptom onset, rather than age at diagnosis, better reflects disease severity and progression, as delays in diagnosis are common due to phenotypic variability and lack of awareness. Therapeutic development for NPC1 has been historically limited, with miglustat approved in some regions for off‐label use and 2‐hydroxypropyl‐β‐cyclodextrin currently under clinical investigation. Recent advances in disease understanding have prompted the development of pharmacodynamic, diagnostic, and prognostic biomarkers to support earlier diagnosis and monitor therapeutic efficacy. Dysregulation of cholesterol homeostasis, neuroinflammation, and neuronal loss have guided biomarker discovery, with promising candidates including 24( S )‐hydroxycholesterol, neurofilament light chain, and bile acid derivatives such as 3β,5α,6β‐trihydroxycholanic acid. Novel lipid biomarkers including N ‐palmitoyl‐ O ‐phosphocholine‐serine and oxysterols such as 7‐ketocholesterol and cholestane‐3β,5α,6β‐triol also show diagnostic value. Despite growing mechanistic insight and a robust pipeline of candidate biomarkers and therapies, NPC1 remains a life‐limiting disease with significant diagnostic and therapeutic gaps. Ongoing clinical trials and translational research are essential to accelerate biomarker qualification and regulatory approval of disease‐modifying treatments. A comprehensive, mechanistically driven approach that integrates molecular, biochemical, and clinical endpoints is key to advancing precision medicine for NPC1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Niemann-Pick Disease, Type CBiomarkersHumansClinical Trials as TopicCholesterolNiemann-Pick C1 ProteinMutation

Stichwörter der Autor:innen

NPC1biomarkercholesterollysosomal lipid storage disorderneuronopathictreatment

Substanzen

BiomarkersCholesterolNiemann-Pick C1 Protein

Autor:innen und Institutionen

  • Purity Health, Columbia, Tennessee, USA.
  • Department of Chemistry, University of Illinois Chicago, Chicago, Illinois, USA.
  • Departments of Pediatrics, Neurological Sciences, Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.
  • University of Minnesota, Department of Pediatrics, Minneapolis, Minnesota, USA.
  • Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, DHHS, Bethesda, Maryland, USA.

ORCID-Profile: Krista Casazza

Förderung

  • NIH HHS
  • Intramural NIH HHS
  • US FDA
  • the RDCRN Data Management and Coordinating Center (DMCC)
  • The Lysosomal Disease Network
  • Lysosomal Disease Network

Zitieren

APA

Casazza, K., Cologna, S. M., Berry-Kravis, E., Jarnes, J., & Porter, F. D. (2025). Biomarker Validation in NPC1 : Foundations for Clinical Trials and Regulatory Alignment. Journal of Inherited Metabolic Disease, 48(5). https://doi.org/10.1002/jimd.70075

Vancouver

Casazza K, Cologna SM, Berry-Kravis E, Jarnes J, Porter FD. Biomarker Validation in NPC1 : Foundations for Clinical Trials and Regulatory Alignment. Journal of Inherited Metabolic Disease. 2025;48(5). doi:10.1002/jimd.70075

BibTeX
@article{Casazza2025,
  author = {Casazza, Krista and Cologna, Stephanie M and Berry-Kravis, Elizabeth and Jarnes, Jeanine and Porter, Forbes D},
  title = {Biomarker Validation in NPC1 : Foundations for Clinical Trials and Regulatory Alignment},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {5},
  doi = {10.1002/jimd.70075}
}
Kostenlos starten →